Acorda Therapeutics Inc. is a biotechnology company founded with the mission to develop and market therapies for neurological conditions, particularly focusing on spinal cord injuries and multiple sclerosis. The company's vision centers on improving the lives of millions affected by nervous system disorders through innovative treatments. Acorda's product portfolio includes INBRIJA®, a therapy for Parkinson's disease, and other regenerative approaches aimed at spinal cord and brain repair. Their market focus is on patients, caregivers, and healthcare professionals dealing with neurological conditions.

Notable figures affiliated with Acorda Therapeutics include its founder and key investors who have supported its mission to bring life-changing therapies to the market. The company has achieved significant milestones, including FDA approval for INBRIJA® and advancements in spinal cord injury treatments. Acorda's impact is reflected in its commitment to maintaining open dialogue with patients and healthcare professionals, driving forward research and development in the biotech field, and striving to make a tangible difference in the quality of life for those with nervous system disorders.